Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-26
2010-10-19
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S297000
Reexamination Certificate
active
07816382
ABSTRACT:
The present invention provides novel urea mimics and analogues of Formula (I):or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and R6are as defined herein. These compounds are selective inhibitors of the human P2Y1receptor which can be used as medicaments.
REFERENCES:
patent: 3118888 (1964-01-01), Giraldi et al.
patent: 3162644 (1964-12-01), Englisch et al.
patent: 4179563 (1979-12-01), Butler
patent: 4186199 (1980-01-01), Glamkowski et al.
patent: 4435391 (1984-03-01), Sasahara et al.
patent: 4663453 (1987-05-01), Glamkowski et al.
patent: 4840947 (1989-06-01), Glamkowski et al.
patent: 4886822 (1989-12-01), Shibuya et al.
patent: 5500424 (1996-03-01), Nagamine et al.
patent: 5547966 (1996-08-01), Atwal et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5691364 (1997-11-01), Buckman et al.
patent: 5708008 (1998-01-01), Audia et al.
patent: 5886004 (1999-03-01), Audia et al.
patent: 6020357 (2000-02-01), Pinto et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6143764 (2000-11-01), Kubo et al.
patent: 6180675 (2001-01-01), Widdowson et al.
patent: 6187797 (2001-02-01), Pruitt et al.
patent: 6329395 (2001-12-01), Dugar et al.
patent: 6586453 (2003-07-01), Dhanoa et al.
patent: 6596746 (2003-07-01), Das et al.
patent: 6656933 (2003-12-01), Hickey
patent: 6825355 (2004-11-01), Das et al.
patent: 6863647 (2005-03-01), Pevarello et al.
patent: 7388021 (2008-06-01), Chao et al.
patent: 2002/0077486 (2002-06-01), Scarborough et al.
patent: 2003/0061667 (2003-04-01), Lim et al.
patent: 2003/0065176 (2003-04-01), Kang et al.
patent: 2003/0153568 (2003-08-01), Cusack et al.
patent: 2003/0195232 (2003-10-01), Kawasaki et al.
patent: 2003/0207870 (2003-11-01), Dumas et al.
patent: 2003/0216396 (2003-11-01), Dumas et al.
patent: 2004/0023961 (2004-02-01), Dumas et al.
patent: 2004/0038992 (2004-02-01), Bemis et al.
patent: 2004/0102636 (2004-05-01), Miller et al.
patent: 2004/0209930 (2004-10-01), Carboni et al.
patent: 2004/0259875 (2004-12-01), Yura et al.
patent: 2005/0009815 (2005-01-01), DeVita et al.
patent: 2005/0012254 (2005-01-01), Hsu
patent: 2005/0119304 (2005-06-01), Yura et al.
patent: 2005/0203146 (2005-09-01), Herpin et al.
patent: 2005/0256161 (2005-11-01), Tempest et al.
patent: 2005/0261244 (2005-11-01), Tuerdi et al.
patent: 2005/0267119 (2005-12-01), Chao et al.
patent: 2006/0173002 (2006-08-01), Sutton et al.
patent: 2006/0293281 (2006-12-01), Qiao et al.
patent: 2006/0293336 (2006-12-01), Sutton et al.
patent: 2006/0293522 (2006-12-01), Sutton
patent: 0 028 489 (1981-05-01), None
patent: 0 129 692 (1985-01-01), None
patent: 0 265 734 (1988-05-01), None
patent: 0 286 979 (1988-10-01), None
patent: 0 638 557 (1995-02-01), None
patent: 1 120 409 (2001-08-01), None
patent: 1 123 918 (2001-08-01), None
patent: 1 402 888 (2004-03-01), None
patent: 1661879 (2006-05-01), None
patent: 1 712 242 (2006-10-01), None
patent: 1 342 550 (1962-12-01), None
patent: 56167649 (1981-12-01), None
patent: 62-280847 (1987-12-01), None
patent: 2001089412 (1988-09-01), None
patent: 3-39740 (1991-02-01), None
patent: 4-319958 (1992-11-01), None
patent: 7-101153 (1995-04-01), None
patent: WO 96/17825 (1996-06-01), None
patent: WO 97/29743 (1997-08-01), None
patent: WO98/18430 (1998-05-01), None
patent: WO 98/37035 (1998-08-01), None
patent: WO 98/57951 (1998-12-01), None
patent: WO 99/31086 (1999-06-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/59506 (2000-10-01), None
patent: WO 00/76495 (2000-12-01), None
patent: WO 00/76970 (2000-12-01), None
patent: WO 01/23358 (2001-04-01), None
patent: WO 01/40231 (2001-06-01), None
patent: WO 01/47919 (2001-07-01), None
patent: WO 01/51490 (2001-07-01), None
patent: WO 01/55146 (2001-08-01), None
patent: WO 01/57008 (2001-08-01), None
patent: WO 01/72751 (2001-10-01), None
patent: WO 02/44145 (2002-06-01), None
patent: WO 02/064211 (2002-08-01), None
patent: WO 02/088090 (2002-11-01), None
patent: WO 02/090352 (2002-11-01), None
patent: WO 03/007955 (2003-01-01), None
patent: WO 03/013517 (2003-02-01), None
patent: WO 03/014064 (2003-02-01), None
patent: WO 03/026652 (2003-04-01), None
patent: WO 03/045920 (2003-06-01), None
patent: WO 03/055484 (2003-07-01), None
patent: WO 03/055848 (2003-07-01), None
patent: WO 03/080553 (2003-10-01), None
patent: WO 2004/002481 (2004-01-01), None
patent: WO 2004/012733 (2004-02-01), None
patent: WO 2004/022529 (2004-03-01), None
patent: WO 2004/046090 (2004-06-01), None
patent: WO 2004/060907 (2004-07-01), None
patent: WO 2004/085433 (2004-10-01), None
patent: WO 2004/110374 (2004-12-01), None
patent: WO 2005/037763 (2005-04-01), None
patent: WO 2005/042488 (2005-05-01), None
patent: WO 2005/063293 (2005-07-01), None
patent: WO2005/070920 (2005-08-01), None
patent: WO 2006/091963 (2006-08-01), None
U.S. Appl. No. 11/872,816, filed Oct. 16, 2007, Lam et al.
Atwal, K.S. et al., “Cardioselective Antiischemic ATP-Sensitive Potassium Channel Openers. 4. Structure-Activity Studies on Benzopyranylcyanoguanidines: Replacement of the Benzopyran Portion”, Journal of Medicinal Chemistry, vol. 39, No. 1, pp. 304-313 (1996).
Bareich, D.C. et al., “Simultaneous In Vitro Assay of the First Four Enzymes in the Fungal Aspartate Pathway Identifies a New Class of Aspartate Kinase Inhibitor”, Chemistry & Biology, vol. 10, pp. 967-973 (2003).
Beaver, D.J. et al., “The Preparation and Bacteriostatic Activity of Substituted Ureas”, J. Am. Chem. Soc., vol. 79, pp. 1236-1245 (1957).
Bensemann, I. et al., “Creation of hydrogen bonded 1D networks by co-crystallization ofN,N′-bis(2-pyridyl)aryldiamines with dicarboxylic acids”, Org. Biomol. Chem., vol. 1, pp. 1425-1434 (2003).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., “Prodrugs as a means to improve the delivery of peptide drugs”, Advanced Drug Delivery Reviews, vol. 8, pp. 1-38 (1992).
Chan, D.M.T. et al., Chapter 5: “Recent Advances in Copper-promoted C-Heteroatom Bond Cross-coupling Reactions with Boronic Acids and Derivatives”, Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine, Wiley-VCH Verlag GmbH & Co., publ., Hall, D.G., ed., pp. 205-240 (2005).
Chou, T.-C. et al., “Quantitative Analysis of Dose-Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors”, Adv. Enzyme Regul., vol. 22, pp. 27-55 (1984).
Cobern, D. et al., “Some Newp-Chlorophenoxycarbanilides and Their Bacteriostatic Activities”, J. Med. Chem., vol. 11, pp. 163-164 (1968).
Duncan, Jr., R.L. et al., “Synthesis of Indolo- and Benzimidazoquinazolines and Benzodiazepines”, Journal of Heterocyclic Chemistry, vol. 10, pp. 65-70 (1973).
Fabre, J.-E. et al., “Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice”, Nature Medicine, vol. 5, No. 10, pp. 1199-1202 (1999).
Gallou, I. et al., “Practical Synthesis of Unsymmetrical Ureas from Isopropenyl Carbamates”, J. Org. Chem., vol. 70, No. 17, pp. 6960-6963 (2005).
Glamkowski, E.J. et al., “Synthesis of 1,2-Dihydroindolo[1,7-ab][1,5]benzodiazepines and .Related Structures (1). A New Heterocyclic Ring System”, J. Heterocyclic Chem., vol. 16, pp. 865-869 (1979).
Glamkowski, E.J. et al., “Tetracyclic Benzodiazepines. 3. Synthesis of the 2,3-Dihydro-1H-quino[1,8-ab][1,5]benzodiazepine Ring System, and Derivatives of Potential Biological Interest”, J. Heterocyclic Chem., vol. 24, pp. 733-737 (1987).
Gramatica, P. et al., “QSAR approach for the selection of congeneric compounds with a similar toxicological mode of action”, Chemosphere, vol. 42, pp. 873-883 (2001).
Gschwend, D.A. et al., “Specificity in Structure-Based Drug Design: Identification
Chao Hannguang J.
Lawrence R. Michael
Ruel Rejean
Sutton James C.
Bristol--Myers Squibb Company
Morris Patricia L
Sun Jing G.
LandOfFree
Linear urea mimics antagonists of P2Y 1 receptor useful in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Linear urea mimics antagonists of P2Y 1 receptor useful in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Linear urea mimics antagonists of P2Y 1 receptor useful in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4192609